Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of At-9283. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA known ✓ | O14965 | 10/20 | 0.58 |
| ▸ | AURKB known ✓ | Q96GD4 | 10/20 | 0.58 |
| ▸ | FLT3 known ✓ | P36888 | 2/20 | 0.58 |
| ▸ | JAK2 known ✓ | O60674 | 1/20 | 0.58 |
| ▸ | ABL1 known ✓ | P00519 | 1/20 | 0.58 |
| ▸ | JAK3 known ✓ | P52333 | 1/20 | 0.58 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.58 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.58 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.58 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.58 |
| ▸ | KDR | P35968 | 2/20 | 0.58 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.58 |
| ▸ | CDC7 | O00311 | 1/20 | 0.58 |
| ▸ | PLK4 | O00444 | 1/20 | 0.58 |
| ▸ | STK25 | O00506 | 1/20 | 0.58 |
| ▸ | GAK | O14976 | 1/20 | 0.58 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.58 |
| ▸ | BUB1 | O43683 | 1/20 | 0.58 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.58 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| At-9283 SCHEMBL546031 | 0.98 | AURKA (0.57) | AURKAAURKBFGFR1FGFR2FGFR3 | |
| At-9283 SCHEMBL545942 | 0.96 | AURKA (0.62) | AURKAAURKBFGFR1FGFR2FGFR3 | |
| At-9283 SCHEMBL546034 | 0.95 | AURKA (0.61) | AURKAAURKBFGFR1FGFR2FGFR3 | |
| At-9283 SCHEMBL546435 | 0.95 | AURKA (0.61) | AURKAAURKBFGFR1FGFR2FGFR3 | |
| SCHEMBL10240197 | 0.94 | AURKA (0.63) | AURKAAURKBFGFR1FGFR2FGFR3 | |
| SCHEMBL10240259 | 0.93 | AURKA (0.60) | AURKAAURKBFGFR1FGFR2FGFR3 | |
| SCHEMBL10240249 | 0.92 | AURKA (0.64) | AURKAAURKBFGFR1FGFR2FGFR3 | |
| At-9283 SCHEMBL546336 | 0.92 | AURKA (0.56) | AURKAAURKBFGFR1FGFR2FGFR3 | |
| At-9283 SCHEMBL545809 | 0.90 | AURKA (0.71) | AURKAAURKBFGFR1FGFR2FGFR3 | |
| At-9283 SCHEMBL29353018 | 0.90 | AURKA (0.71) | AURKAAURKBFGFR1FGFR2FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8778936-B2 | Pyrazole compounds that modulate the activity of CDK, GSK and aurora kinases | ASTEX THERAPEUTICS LIMITED (GB) | 2014-07-15 | — | — | US | disclosed |
| US-8435970-B2 | Title compound is drug AT-9283, inhibitor of Cyclin Dependent Kinases (CDK kinases), Aurora kinases and Glycogen Synthase Kinase-3 (GSK3) | ASTEX THERAPEUTICS LIMITED (GB) | 2013-05-07 | — | — | US | disclosed |
| US-8399442-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2013-03-19 | — | — | US | disclosed |
| US-20120190673-A1 | PYRAZOLE COMPOUNDS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2012-07-26 | — | — | US | disclosed |
| US-8110573-B2 | Enzyme inhibitors; Cyclin-Dependent Kinases (CDK), Glycogen Synthase Kinases (GSK); -cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea salt for example; anticancer agents | ASTEX THERAPEUTICS LIMITED (GB) | 2012-02-07 | — | — | US | disclosed |
| EP-2395000-A1 | Benzimidazole compounds that modulate the activity of CDK, GSK and aurora kinases | Astex Therapeutics Limited (GB) | 2011-12-14 | — | — | EP | disclosed |
| US-20110159111-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-06-30 | — | — | US | disclosed |
| US-20100055094-A1 | PHARMACEUTICAL COMBINATIONS OF 1-CYCLOPROPYL-3- [3-(5-M0RPHOOLIN-4-YL-METHYL-1H-BENZOIMIDAZOL-2-YL)- LH-1-PYRAZOL-4-YL]- UREA | ASTEX THERAPEUTICS LIMITED (GB) | 2010-03-04 | — | — | US | disclosed |
| US-20100004232-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS LIMITED (UK) | 2010-01-07 | — | — | US | disclosed |
| EP-2049119-A2 | PHARMACEUTICAL COMBINATIONS OF 1-CYCLOPROPYL-3-[3-(5-MORPHOOLIN-4-YLMETHYL-1H-BENZOIMIDAZOL-2-YL)-1H-1-PYRAZOL-4-YL]-UREA | Astex Therapeutics Limited (GB) | 2009-04-22 | — | — | EP | disclosed |
| EP-2043635-A2 | PHARMACEUTICAL COMBINATIONS | Astex Therapeutics Limited (GB) | 2009-04-08 | — | — | EP | disclosed |
| EP-1968579-A1 | PHARMACEUTICAL COMPOUNDS | Astex Therapeutics Limited (GB) | 2008-09-17 | — | — | EP | disclosed |
| US-20080132495-A1 | Pyrazole Compounds that Modulate the Activity of Cdk, Gsk and Aurora Kinases | ASTEX THERAPEUTICS LIMITED (GB) | 2008-06-05 | — | — | US | disclosed |
| WO-2008001101-A2 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-01-03 | — | — | WO | disclosed |
| WO-2008001115-A2 | PHARMACEUTICAL COMBINATIONS OF 1-CYCLOPROPYL-3- [3- (5-M0RPHOOLIN-4-YLMETHYL-1H-BENZOIMIDAZOL-2-YL) -LH-1-PYRAZOL- 4-YL] -UREA | ASTEX THERAPEUTICS LIMITED (GB) | 2008-01-03 | — | — | WO | disclosed |
| EP-1833819-A1 | PYRAZOLE COMPOUNDS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES | Astex Therapeutics Limited (GB) | 2007-09-19 | — | — | EP | disclosed |
| WO-2007077435-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2007-07-12 | — | — | WO | disclosed |
| WO-2006070195-A1 | PYRAZOLE COMPOUNDS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004232-A1 | Pharmaceutical Compounds | ERBB3, ABL1, RET | AURKA 98/4885AURKB 67/4885FLT3 52/4885 |
| US-20120190673-A1 | PYRAZOLE COMPOUNDS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES | CDK3, CDK1, AURKA | AURKA 3/4885AURKB 9/4885FLT3 795/4885 |
| US-20080132495-A1 | Pyrazole Compounds that Modulate the Activity of Cdk, Gsk and Aurora Kinases | CDK3, CDK1, AURKA | AURKA 3/4885AURKB 9/4885FLT3 795/4885 |
| US-20100055094-A1 | PHARMACEUTICAL COMBINATIONS OF 1-CYCLOPROPYL-3- [3-(5-M0RPHOOLIN-4-YL-METHYL-1H-BENZOIMIDAZOL-2-YL)- LH-1-PYRAZOL-4-YL]- UREA | LDHA, LDHB, PDK4 | AURKA 261/4885AURKB 714/4885FLT3 366/4885 |
| US-20110159111-A1 | PHARMACEUTICAL COMBINATIONS | SLC10A1, CYP11B2, SDHB | AURKA 1051/4885AURKB 878/4885FLT3 815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.